Septerna, Inc. SEPN

Septerna (SEPN) heads into a busy conference stretch, with investor attention drawn to upcoming presentations at Wells Fargo’s 21st Annual Healthcare Conference on September 8 and Cantor Fitzgerald’s Global Healthcare Conference on September 10. At a last close of US$38.51, Septerna’s recent moves tell a mixed story, with the share price return up 2.01% over 1 day and 4.79% over 7 days, yet down 13.46% over 30 days. The year to date share price return of 37.63% and 1 year total shareholder...

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s common stock to Rajiv Patni, M.D., the Company’s newly appointed Chief Medical Officer, under the Company’s 2026 Inducement Plan (the “Inducement Plan”). The inducement grant was effective as of September 8, 2026. The award was granted as an inducement material to Dr. Patni’s employme

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare ConferenceFireside chat on Tuesday, September 8, 2026, at 8:00 a.m. ET Cantor Global Healthcare Conference 2026Fireside chat on Thursday, September 10, 2026

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations. “We are thrilled

Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highli

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list. TheFly reported on June 11 that Guggenheim began coverage of SEPN with a Buy rating and assigned the company a $52 price target. In […]

SOUTH SAN FRANCISCO, Calif., June 08, 2026--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago.

Protego Biopharma, Inc., a clinical-stage biotechnology company focused on developing small-molecule drugs that target protein misfolding diseases, today announced the appointment of Jae B. Kim, MD, as its Chief Medical Officer (CMO). Dr. Kim joins Protego after serving as Chief Medical Officer of Septerna since 2024.

Septerna, Inc. ( NASDAQ:SEPN ) shareholders will have a reason to smile today, with the analysts making substantial...

Septerna, Inc. ( NASDAQ:SEPN ) defied analyst predictions to release its first-quarter results, which were ahead of...

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pion

Septerna, Inc. recently announced that CEO Jeffrey Finer will present the company’s clinical-stage GPCR drug discovery programs at the Bank of America Securities Health Care Conference on May 12, 2026, with a live webcast available on its investor website. A new positive coverage initiation by a well-regarded Stifel analyst, combined with this high-profile conference appearance, underscores growing institutional attention to Septerna’s pipeline story and investor communications. We will now...